- A +

News & Press Releases

2017-08-01 / Press release

GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

2017-07-28 / Press release

GenSight Biologics Reports Interim Financial Results for the First Half of 2017

2017-06-23 / Press release

Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

2017-06-23 / Press release

GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe

2017-06-22 / Press release

GenSight Biologics launches a capital increase of approximately €20 million

2017-06-14 / Press release

GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of LHON

2017-05-08 / Press release

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

2017-05-03 / Press release

GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer

2017-04-28 / Press release

GenSight Biologics Announces the Filing of its 2016 Registration Document

2017-04-27 / Press release

GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit

2017-04-20 / Press release

GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Academy of Neurology

2017-04-19 / Press release

GenSight Biologics to Attend Upcoming Investor Conferences

2017-03-28 / Press release

GenSight Biologics to Present Data on GS010 at the 43rd Annual Meeting of NANOS

2017-03-13 / Press release

GenSight Biologics Reports Full Year 2016 Financial Results

2017-02-21 / Press release

GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of LHON

2017-01-31 / Press release

GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa

2016-12-20 / Press release

GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) 

2016-10-13 / Press release

GenSight Biologics reports its cash position as of September 30, 2016

2016-09-08 / Press release

GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy

2016-09-01 / Press release

The European Medicines Agency (EMA), has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa.

2016-08-11 / Press release

GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option.

2016-08-11 / Press release

GenSight Biologics announces the implementation of  a liquidity contract with Oddo & Cie

2016-08-11 / Press release

Total size of the offering in the context of the Company’s IPO increased to 5,655,859 new shares, i.e. €45.2 million.

2016-07-13 / Press release

GenSight Biologics announces successful IPO on Euronext Paris : €40 million raised, largest French biotech IPO YTD.

2016-07-05 / Press release

GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris.

2016-06-08 / Press release

Confirmation of the good safety and tolerability profile of GS010 and improvement of visual acuity in patients with an onset of disease of less than 2 years.

2016-05-24 / Press release

GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext's regulated market in Paris.

2016-02-29 / Press release

GenSight Biologics announced enrollment of the first patient in both RESCUE and REVERSE, two pivotal Phase III trials with lead product candidate GS010.

2015-09-10 / Press release

GenSight Biologics announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for two Phase III clinical trials of GS010.

2015-07-23 / Press release

GenSight Biologics announced that it has completed a Series B preferred stock financing of approximately $36 million.

2015-07-06 / Press release

GenSight Biologics Appoints Thomas Gidoin as Chief Financial Officer & Michael Wyzga to Board of Directors.

2015-01-06 / Press release

GenSight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total €18.5 million funding for SIGHT AGAIN as part of the Investment for the Future.

2014-05-06 / Press release

GenSight Biologics announces the appointment of Jean-Philippe Combal as Chief Operating Officer. 

2013-04-08 / Press release

GenSight Biologics announced today the closing of a €32 million Series A financin for Ophthalmic Gene Therapy.